Qureight and Remedy Cell partner to integrate deep learning platform into Phase 1b study of RC-0315 in IPF
Qureight Ltd, a Core Imaging Laboratory with deep-learning analytics, and Remedy Cell, a clinical-stage biopharmaceutical company focused on the development of proprietary cell-derived therapies for fibrotic diseases, have partnered to validate RC-0315’s mechanism of action in idiopathic pulmonary fibrosis (IPF). The primary objective of the RC-0315 Phase 1b clinical study is to measure drug safety…